Literature DB >> 21779490

H-ras localizes to cell nuclei and varies with the cell cycle.

Sara Contente1, Tze-Jou Annie Yeh, Robert M Friedman.   

Abstract

H-Ras functions as a signal switch molecule in numerous signaling pathways in the cytoplasm, requiring H-Ras localization to the inner surface of the cytoplasmic membrane, and H-Ras is considered to be a cytoplasmic protein. Immunoblot studies of cells transformed by overexpression of c-H-ras indicated that H-Ras protein was present in both cytoplasmic and nuclear extracts, suggesting a possible correlation of nuclear H-Ras and cellular transformation. Unexpectedly, additional studies revealed that H-Ras protein was also present in the nuclei of nontransformed and primary mouse cells, which do not overexpress H-Ras. Mouse fibroblast NIH 3T3 cells, L cells, and a primary fibroblast line all had H-Ras present in both cytoplasmic and nuclear extracts. Nuclear extracts of cells synchronized by growth without serum displayed an increasing amount of H-Ras and cyclin D1 as cells grew after serum addition. Treatment with farnesyltransferase inhibitor caused loss of H-Ras from the nucleus. Immunofluorescence in situ studies of nuclei from synchronized cultures showed that H-Ras protein appeared in and disappeared from the nuclei as the cells moved through the growth cycle. This cycling occurred in both nontransformed and ras-transformed cells. Flow cytometry measurements on parallel cultures revealed that the time point at which the greatest percentage of cells were in S phase, for each line, corresponded to appearance of a noticeably stronger in situ signal for H-Ras. H-Ras may participate in nuclear signaling pathways associated with replication in addition to its cytoplasmic signaling functions.

Entities:  

Keywords:  Ras; cell cycle; cyclin D1; farnesyltransferase inhibitor; nuclear localization

Year:  2011        PMID: 21779490      PMCID: PMC3111243          DOI: 10.1177/1947601911405042

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  24 in total

Review 1.  Ras-dependent cell cycle commitment during G2 phase.

Authors:  M Hitomi; D W Stacey
Journal:  FEBS Lett       Date:  2001-02-16       Impact factor: 4.124

2.  Expression of the H-ras proto-oncogene is controlled by alternative splicing.

Authors:  J B Cohen; S D Broz; A D Levinson
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

3.  Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.

Authors:  M M Moasser; L Sepp-Lorenzino; N E Kohl; A Oliff; A Balog; D S Su; S J Danishefsky; N Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

4.  Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells.

Authors:  J J Liu; J R Chao; M C Jiang; S Y Ng; J J Yen; H F Yang-Yen
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

5.  Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene.

Authors:  D Samid; E H Chang; R M Friedman
Journal:  Biochem Biophys Res Commun       Date:  1984-02-29       Impact factor: 3.575

6.  Nuclear Ras: unexpected subcellular distribution of oncogenic forms.

Authors:  G Wurzer; W Mosgoeller; M Chabicovsky; C Cerni; J Wesierska-Gadek
Journal:  J Cell Biochem Suppl       Date:  2001

7.  Reversion by deletion of transforming oncogene following interferon-beta and retinoic acid treatment.

Authors:  R M Friedman; A Yeh; P Gutman; S Contente; K Kenyon
Journal:  J Interferon Cytokine Res       Date:  1997-10       Impact factor: 2.607

8.  Cellular ras and cyclin D1 are required during different cell cycle periods in cycling NIH 3T3 cells.

Authors:  M Hitomi; D W Stacey
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

9.  Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus.

Authors:  Sònia Guil; Núria de La Iglesia; Juan Fernández-Larrea; Daniel Cifuentes; Juan C Ferrer; Joan J Guinovart; Montse Bach-Elias
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

10.  Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus.

Authors:  E H Chang; M E Furth; E M Scolnick; D R Lowy
Journal:  Nature       Date:  1982-06-10       Impact factor: 49.962

View more
  4 in total

1.  Analysis of K-Ras Interactions by Biotin Ligase Tagging.

Authors:  Christopher Ritchie; Andrew Mack; Logan Harper; Ayna Alfadhli; Philip J S Stork; Xiaolin Nan; Eric Barklis
Journal:  Cancer Genomics Proteomics       Date:  2017 Jul-Aug       Impact factor: 4.069

2.  Ras Regulates Rb via NORE1A.

Authors:  Thibaut Barnoud; Howard Donninger; Geoffrey J Clark
Journal:  J Biol Chem       Date:  2015-12-16       Impact factor: 5.157

3.  Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS.

Authors:  Arjun Kalvala; Pierre Wallet; Lu Yang; Chongkai Wang; Haiqing Li; Arin Nam; Anusha Nathan; Isa Mambetsariev; Valeriy Poroyko; Hanlin Gao; Peiguo Chu; Martin Sattler; Andrea Bild; Edwin R Manuel; Peter P Lee; Mohit Kumar Jolly; Prakash Kulkarni; Ravi Salgia
Journal:  J Clin Med       Date:  2019-10-18       Impact factor: 4.241

4.  Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.

Authors:  Patience Odeniyide; Marielle E Yohe; Kai Pollard; Angelina V Vaseva; Ana Calizo; Lindy Zhang; Fausto J Rodriguez; John M Gross; Amy N Allen; Xiaolin Wan; Romel Somwar; Karisa C Schreck; Linda Kessler; Jiawan Wang; Christine A Pratilas
Journal:  Oncogene       Date:  2022-04-22       Impact factor: 8.756

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.